Patents by Inventor Amin NEZAMI

Amin NEZAMI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190167634
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Application
    Filed: July 3, 2018
    Publication date: June 6, 2019
    Inventor: Mohammed Amin Nezami
  • Publication number: 20180360272
    Abstract: An electric motor-operated food processor has a base unit having an electric motor and a preparation vessel that can be arranged on the base unit. A heater and agitator are allocated to the preparation vessel. The food processor can have a distillation apparatus that can be connected with the preparation vessel. The distillation apparatus has a steam receptacle, a condenser and a liquid dispenser. The preparation vessel and steam receptacle are connected in terms of flow when the preparation vessel and distillation apparatus are in a connected state.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 20, 2018
    Applicant: Vorwerk & Co. Interholding GmbH
    Inventors: Mirko KVESIC, Janik NACHBARSCHULTE, Thomas ERNER, Amin NEZAMI, Mathias VARNHORST, Daniel KATAGAROV, Philipp BETTENHAUSEN
  • Patent number: 10016392
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: July 10, 2018
    Assignee: Research Cancer Institute of America
    Inventor: Mohammed Amin Nezami
  • Publication number: 20170014376
    Abstract: A method and compositions for treating cancer is described using at least two epigenetic modifiers. In various embodiments, hyperbaric oxygen therapy and glycolytic inhibition therapy are used as well.
    Type: Application
    Filed: March 21, 2016
    Publication date: January 19, 2017
    Inventor: Mohammad Amin Nezami
  • Publication number: 20170007573
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Application
    Filed: June 13, 2016
    Publication date: January 12, 2017
    Inventor: Mohammed Amin Nezami
  • Patent number: 9364500
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: June 14, 2016
    Assignee: Research Cancer Institute of America
    Inventor: Mohammed Amin Nezami
  • Publication number: 20150090267
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 2, 2015
    Inventor: Mohammed Amin Nezami
  • Patent number: 8933078
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Grant
    Filed: November 26, 2011
    Date of Patent: January 13, 2015
    Assignee: Research Cancer Institute of America
    Inventor: Mohammed Amin Nezami
  • Publication number: 20130014753
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Application
    Filed: November 26, 2011
    Publication date: January 17, 2013
    Inventor: Mohammed Amin Nezami